The use of data from the real world to address clinical and policy-relevant questions that
cannot be answered using data from clinical trials is garnering increased interest. Indeed …

Context Invasive bladder cancer is a frequently occurring disease with a high mortality rate
despite optimal treatment. The European Association of Urology (EAU) Muscle-invasive and …

Radical treatment of many solid tumours has moved from surgery to multimodal organ
preservation strategies combining systemic and local treatments. Trimodality bladder …

Objectives To test the feasibility of a randomised trial in muscle‐invasive bladder cancer
(MIBC) and compare outcomes in patients who receive neoadjuvant chemotherapy followed …

Background Two radiotherapy fractionation schedules are used to treat locally advanced
bladder cancer: 64 Gy in 32 fractions over 6· 5 weeks and a hypofractionated schedule of 55 …

The standard of care for non-muscle-invasive bladder cancer (NMIBC) is transurethral
resection followed by risk stratified use of intravesical immune-or chemotherapy and for …

The European Association of Urology (EAU) Guidelines Panel for Muscle-invasive and
Metastatic Bladder Cancer (MIBC) has prepared these guidelines to help urologists assess …

Background Chemoradiation therapy (CRT) has been increasingly reported as a possible
alternative to total cystectomy (TC) for localized bladder cancer (BC). Pembrolizumab is the …

Bladder preservation with trimodality treatment (TMT) is an alternative strategy to radical
cystectomy (RC) for the management of localised muscle invasive bladder cancer (MIBC) …

Purpose Organ-confined muscle-invasive bladder cancer is treated with cystectomy or
bladder preservation techniques, including radiation therapy. There are currently no …